|Dr. Carole S. Ben-Maimon M.D.||CEO, Pres & Director||663.43k||N/A||1959|
|Mr. Michael Celano CPA||Sec. & CFO||447.61k||N/A||1959|
|Mr. John Berman||VP of Fin. & Operations||N/A||N/A||N/A|
|Ms. Jennifer Spokes Johansson||VP of Regulatory Affairs & Counsel||N/A||N/A||N/A|
|Dr. Nancy M. Ruiz||Chief Medical Officer||N/A||N/A||N/A|
|Mr. Francis Michael Conway||VP & Controller||N/A||N/A||N/A|
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.